These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18298509)

  • 21. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.
    Stockburger M; Krebs A; Nitardy A; Habedank D; Celebi O; Knaus T; Dietz R
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S16-20. PubMed ID: 19250084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implantable cardioverter defibrillators in pediatric patients: off-label devices for orphan diseases.
    Rhee EK
    J Cardiovasc Electrophysiol; 2005 Jan; 16(1):74-5. PubMed ID: 15673392
    [No Abstract]   [Full Text] [Related]  

  • 23. Tools and strategies for the reduction of inappropriate implantable cardioverter defibrillator shocks.
    Tzeis S; Andrikopoulos G; Kolb C; Vardas PE
    Europace; 2008 Nov; 10(11):1256-65. PubMed ID: 18708639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of implantable defibrillator longevity under clinical circumstances: implications for device selection.
    Knops P; Theuns DA; Res JC; Jordaens L
    Pacing Clin Electrophysiol; 2009 Oct; 32(10):1276-85. PubMed ID: 19796344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: Predictors of all-cause mortality for patients with chronic Chagas' heart disease receiving implantable cardioverter defibrillator therapy.
    Cardinalli-Neto A; Bestetti RB; Cordeiro JA
    J Cardiovasc Electrophysiol; 2008 Apr; 19(4):E34-5. PubMed ID: 18298517
    [No Abstract]   [Full Text] [Related]  

  • 26. Implantable cardioverter defibrillators: do women fare worse than men? Gender comparison in the INTRINSIC RV trial.
    Russo AM; Day JD; Stolen K; Mullin CM; Doraiswamy V; Lerew DL; Olshansky B
    J Cardiovasc Electrophysiol; 2009 Sep; 20(9):973-8. PubMed ID: 19470037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clustering of ventricular arrhythmias: a therapeutic opportunity or strictly a marker of poor prognosis?
    Curtis AB
    J Cardiovasc Electrophysiol; 2006 Dec; 17(12):1307-9. PubMed ID: 17034407
    [No Abstract]   [Full Text] [Related]  

  • 28. Pre-discharge defibrillation testing: clinically important or obsolete?
    Sturdivant JL; Gold MR
    Europace; 2012 Feb; 14(2):155-6. PubMed ID: 22080474
    [No Abstract]   [Full Text] [Related]  

  • 29. Jumping in before the water is hot: the need to support randomized controlled clinical trials.
    Epstein AE
    J Cardiovasc Electrophysiol; 2004 Aug; 15(8):867-9. PubMed ID: 15333076
    [No Abstract]   [Full Text] [Related]  

  • 30. Does size really matter? A comparison of the Riata lead family based on size and its relation to performance.
    Corbisiero R; Armbruster R
    Pacing Clin Electrophysiol; 2008 Jun; 31(6):722-6. PubMed ID: 18507545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatal complications of pacemaker and implantable cardioverter-defibrillator implantation: medical malpractice?
    Schulz N; Püschel K; Turk EE
    Interact Cardiovasc Thorac Surg; 2009 Apr; 8(4):444-8. PubMed ID: 19168462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simpler is better? Full circle in our attempt to decrease cardioverter defibrillator inappropriate shocks in the young.
    Kugler JD
    J Cardiovasc Electrophysiol; 2009 Mar; 20(3):291-2. PubMed ID: 19175844
    [No Abstract]   [Full Text] [Related]  

  • 33. [ICD therapy 2005--from implantation to follow-up measures].
    Bänsch D; Kuck KH
    Herz; 2005 Nov; 30(7):589-90. PubMed ID: 16333582
    [No Abstract]   [Full Text] [Related]  

  • 34. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.
    Daubert JP; Zareba W; Cannom DS; McNitt S; Rosero SZ; Wang P; Schuger C; Steinberg JS; Higgins SL; Wilber DJ; Klein H; Andrews ML; Hall WJ; Moss AJ;
    J Am Coll Cardiol; 2008 Apr; 51(14):1357-65. PubMed ID: 18387436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.
    Roes SD; Borleffs CJ; van der Geest RJ; Westenberg JJ; Marsan NA; Kaandorp TA; Reiber JH; Zeppenfeld K; Lamb HJ; de Roos A; Schalij MJ; Bax JJ
    Circ Cardiovasc Imaging; 2009 May; 2(3):183-90. PubMed ID: 19808591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. It is time to check estimated glomerular filtration rate level in implantable cardioverter-defibrillator patients.
    Zareba W
    Europace; 2009 Nov; 11(11):1415-6. PubMed ID: 19880405
    [No Abstract]   [Full Text] [Related]  

  • 37. Implantable cardioverter-defibrillators and chronic kidney disease.
    Saravanan P; Lang C; Davidson N
    J Cardiovasc Electrophysiol; 2009 Mar; 20(3):E60; author reply E61. PubMed ID: 19271291
    [No Abstract]   [Full Text] [Related]  

  • 38. Low referral rate for prophylactic implantation of cardioverter-defibrillators in a tertiary care medical center.
    Bradfield J; Warner A; Bersohn MM
    Pacing Clin Electrophysiol; 2009 Mar; 32 Suppl 1():S194-7. PubMed ID: 19250092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Difficult AV optimization in a patient with a biventricular implantable cardioverter defibrillator].
    Israel CW; Ehrlich JR; Britten M
    Herzschrittmacherther Elektrophysiol; 2006 Sep; 17(3):174-9. PubMed ID: 16969731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost advantage of different cardioverter-defibrillator devices.
    Veenhuyzen GD
    J Am Coll Cardiol; 2006 Jul; 48(2):418-9; author reply 419. PubMed ID: 16843205
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.